Buscar
01/02/2026
IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC
Christoph, D, Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, R, Stencel, K, Tarruella, MM, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Cuchelkar, V, Graupner, V, Kaul, M, Lin, YC, Chakrabarti, D, Bhatt, K, Reck, M. IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).
01/02/2026
Socioeconomic Deprivation in Ischemic Stroke Treated With Endovascular Thrombectomy: Not All Recoveries Are Equal
Montalvo, C, Garcia-Tornel, A, Olive-Gadea, M, Rodrigo-Gisbert, M, Requena, M, Rizzo, F, Rodriguez-Luna, D, Rodriguez-Villatoro, N, Pagola, J, Simonetti, R, de la Ossa, NP, Camps-Renom, P, Canovas, D, Flores, A, Rodriguez-Campello, A, Silva, Y, Urra, X, Purroy, F, Bustamante, A, Salvat-Plana, M, Cardona, P, Molina, C, Rubiera, M, Ribo, M. Socioeconomic Deprivation in Ischemic Stroke Treated With Endovascular Thrombectomy: Not All Recoveries Are Equal. STROKE. 2026; 57(2)DOI:10.1161/STROKEAHA.125.052865. PMID:41208686. IF:8.900(Q1/1D).
01/02/2026
White Matter Hyperintensities Are Associated with Worse Outcomes but Not Greater Cerebral Edema or Hemorrhagic Transformation After Large Vessel Occlusion Stroke
Dietz, S, Avula, A, Kumar, A, Petersen, N, Guasch-Jimenez, M, Slowik, A, Wrona, P, Dhar, R. White Matter Hyperintensities Are Associated with Worse Outcomes but Not Greater Cerebral Edema or Hemorrhagic Transformation After Large Vessel Occlusion Stroke. STROKE. 2026; 57(SUPPL_1)DOI:10.1161/str.57.suppl_1.DP035. PMID:. IF:8.900(Q1/1D).
01/02/2026
Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report
Rodríguez-Fraga, P, Cascos, E, Cuartas, A, Espadaler, I. Cardiac plasmacytoma with extensive infiltration: multimodal diagnosis and therapeutic challenges: a case report. European Heart Journal-Case Reports. 2026; 10(2)DOI:10.1093/ehjcr/ytag102. PMID:41728229. IF:(Q/D).
01/02/2026
Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
Döhner, H, Schuh, AC, Recher, C, O'Nions, J, Aldoss, I, Piérola, AA, Allred, AJ, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Daskalakis, N, Della Porta, MG, D'Souza, A, Dugan, J, Esteve, J, Fathi, AT, Ferrante, L, Gaj, S, Garciaz, S, Diaz, AG, Salamero, O, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Paniagua, SG, Sackey, N, Sauer, T, Shastri, PN, Searle, E, Tovar, N, Trancucci, D, Vallet, N, Vaughan, L, Vyas, P, Wei, AH, Rölling, C. Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).
01/02/2026
Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis
Lopez-Pereira, P, Domínguez, SR, Martin-Moro, F, Caballero, AC, García, AL, Benito, BD, Sarto, MF, Vicente, FD, Marín, JL, Marino, SP, Jiménez-Ubieto, A, Cabirta, A, Gutiérrez, NC, Chulvi, MJL, Puyuelo, A, Prat, AM, Coello, AP, García-Lerma, E, Vilchez, SM. Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis. BONE MARROW TRANSPLANTATION. 2026; 61(2)DOI:10.1038/s41409-025-02772-2. PMID:41310181. IF:5.200(Q1/1D).
01/02/2026
Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
Westin, J, Chavez, JC, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, García-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).
01/02/2026
The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review
Di Bello, F, Gallioli, A, Pecoraro, A, Prudhomme, T, Piana, A, Marco, BB, Haberal, HB, Dönmez, MI, Lopez-Abad, A, Cannoletta, D, Mancon, S, Guirado, L, Facundo, C, Kanashiro, AK, Gavrilov, P, Rodriguez-Faba, O, Gaya, JM, Breda, A, Territo, A. The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review. Minerva Urology And Nephrology. 2026; 78(1)DOI:10.23736/S2724-6051.25.06559-0. PMID:41697205. IF:4.200(Q1/2D).